Publications

• Homeobox B13 G84E Mutation and Prostate Cancer Risk. 2018 Dec: European Eurology EURURO-8131; No. of Pages 12. Tommy Nyberg a,*, Koveela Govindasami b, Goska Leslie a, Tokhir Dadaev b, Elizabeth Bancroft b,c, Holly Ni Raghallaigh b, Mark N. Brook b, Nafisa Hussain b, Diana Keating b, Andrew Lee a, Romayne McMahon b, Angela Morgan b,c, Andrea Mullen b, Andrea Osborne b, Reshma Rageevakumar b, The UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai b,y, Rosalind Eeles b,c,y, Antonis C. Antoniou.

• Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. (2016) Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.
• Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk. (2016). MacInnis RJ1,2, Schmidt DF2, Makalic E2, Severi G3,4,5, FitzGerald LM6, Reumann M7,8, Kapuscinski MK2, Kowalczyk A9,10, Zhou Z11, Goudey B11, Qian G10, Bui QM2, Park DJ12,13, Freeman A2, Southey MC12, Al Olama AA14, Kote-Jarai Z15, Eeles RA, Hopper JL16,17, Giles GG1,2; UK Genetic Prostate Cancer Study Collaborators.
• High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. (2015). Castro E1, Jugurnauth-Little S2, Karlsson Q2, Al-Shahrour F3, Piñeiro-Yañez E3, Van de Poll F4, Leongamornlert D2, Dadaev T2, Govindasami K2, Guy M2, Eeles R5, Kote-Jarai Z2; UKGPCS, EMBRACE and IMPACT studies. Ann Oncol. 2015 Nov;26(11):2293-300. doi: 10.1093/annonc/mdv356. Epub 2015 Sep 7
• Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. (2015) Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z. Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29
• Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. (2015). Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M, Hamdy FC, Donovan JL, Neal DE, Lane JA, Dearnaley D, Wilkinson RA, Sawyer EJ, Morgan A; The UK Genetic Prostate Cancer Study Collaborators; the ProtecT Study Group, Antoniou AC, Eeles RA. Ann Oncol. 2015 Jan 16. pii: mdv004. Epub ahead of print
• Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. (2015). Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. Epub 2015 Apr 2.PMID:25837820
• Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. (2014). Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C, Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D, Govindasami K, Guy M, Sawyer E, Wilkinson R; UKGPCS Collaborators, Antoniou AC, Eeles R, Kote-Jarai Z. Br J Cancer. 2014 Mar 18;110(6):1663-72. PMID: 24556621 
• Commentary on "Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. (2014). Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study. Urol Oncol. Feb; 32(2):211. PMID: 24445293 
• Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. (2013). Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russel R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA. Hum Mol Genet. Jun 15;22(12):2520-8. PMID:23535824 
• Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. (2013). Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF. Nat Genet. Apr; 45(4):385-91, 391e1-2. PMID:23535732 
• A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013). Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. Hum Mol Genet, Jan 15. PMID:23065704
• Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. (2013). Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russel R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA. Hum Mol Genet. Jun 15;22(12):2520-8. PMID:23535824 
• Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. (2013). Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF. Nat Genet. Apr; 45(4):385-91, 391e1-2. PMID:23535732 
• A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013). Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. Hum Mol Genet, Jan 15. PMID:23065704 
• Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. (2013). Goh CL, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Thomas K, Selvadurai ED, Woode-Amissah R, Dadaev T, Mahmud N, Castro E, Olmos D, Guy M, Govindasami K, O'Brien LT, Hall AL, Wilkinson RA, Sawyer EJ, Al Olama AA, Easton DF, Kote-Jarai Z, Parker CC, Eeles RA. BJU Int, Jan 15. PMID:23320731 
• Germline BRCA1 mutations increase prostate cancer risk. (2012). Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D; The UKGPCS Collaborators, Goldgar D, Eeles R, Kote-Jarai Z.Br J Cancer, Apr 19 [Epub ahead of print] 

• Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). (2011) Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Thibodeau SN, McDonnell SK, Schaid DJ, Wiklund F, Grönberg H, Emanuelsson M, Whittemore AS, Oakley-Girvan I, Hsieh CL, Wahlfors T, Tammela T, Schleutker J, Catalona WJ, Zheng SL, Ostrander EA, Isaacs WB, Xu J; International Consortium for Prostate Cancer Genetics. Hum Genet. Dec 25. [Epub ahead of print] PMID: 22198737
• Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. (2011) Batra J, Lose F, O'Mara T, Marquart L, Stephens C, Alexander K, Srinivasan S, Eeles RA, Easton DF, Al Olama AA, Kote-Jarai Z, Guy M, Muir K, Lophatananon A, Rahman AA, Neal DE, Hamdy FC, Donovan JL, Chambers S, Gardiner RA, Aitken J, Yaxley J, Kedda MA, Clements JA, Spurdle AB. PLoS One. [Epub 2011 Nov 23] PMID: 22132073
• BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.(2011) Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D; The UKGPCS Collaborators, Goldgar D, Eeles R. British Journal of Cancer, Sep 27. [Epub ahead of print]
• A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. (2011) Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Al Olama AA, McGuffog L, Kote-Jarai Z, Guy M, O'Brien LT, Hall AL, Wilkinson RA, Sawyer E, Ardern-Jones AT, Dearnaley DP, Horwich A, Khoo VS, Parker CC, Huddart RA, Van As N, McCredie MR, English DR, Giles GG, Hopper JL, Easton DF. Genet Epidemiol. 35:549-56
• Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. (2011) Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dörk T, Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Røder MA, Tybjærg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; The UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource; The PRACTICAL Consortium, Easton DF, Eeles RA. Nature Genetics 43:785-91
• Genome-wide association study identifies new prostate cancer susceptibility loci. (2011) Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, Stram DO, Eeles RA, Easton DF, Giles G, Hopper JL, Neal DE, Hamdy FC, Donovan JL, Muir K, Al Olama AA, Kote-Jarai Z, Guy M, Severi G, Grönberg H, Isaacs WB, Karlsson R, Wiklund F, Xu J, Allen NE, Andriole GL, Barricarte A, Boeing H, Bas Bueno-de-Mesquita H, Crawford ED, Diver WR, Gonzalez CA, Gaziano JM, Giovannucci EL, Johansson M, Le Marchand L, Ma J, Sieri S, Stattin P, Stampfer MJ, Tjonneland A, Vineis P, Virtamo J, Vogel U, Weinstein SJ, Yeager M, Thun MJ, Kolonel LN, Henderson BE, Albanes D, Hayes RB, Spencer Feigelson H, Riboli E, Hunter DJ, Chanock SJ, Haiman CA, Kraft P. Hum. Mol. Genet. 20:3867-75
• Common variation in Kallikrein genes KLK5, KLK6, KLK12 and KLK13 and risk of prostate cancer and tumour aggressiveness. (2011) Lose F, Batra J, O’Mara T, Fahey P, Marquart L, Eeles RA, Easton DF, Amin Al Olama A, Kote-Jarai Z, Guy M, Muir K, Lophatananon A, Rahman AA, Neal DE, Hamdy FC, Donovan JL,  Chambers S, Gardiner RA, Aitken JF, Yaxley J, Alexander K, Clements JA, Spurdle AB, Kedda MA, and the Australian Prostate Cancer BioResource. Urol Oncol. Jul 7. [Epub ahead of print]
• Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. (2011) Kote-Jarai Z, Amin Al Olama A, Leongamornlert D, Tymrakiewicz M, Saunders E, Guy M, Giles GG, Severi G, Southey M, Hopper JL, Sit KC, Harris JM, Batra J, Spurdle AB, Clements JA, Hamdy F, Neal D, Donovan J, Muir K, Pharoah PD, Chanock SJ, Brown N, Benlloch S, Castro E, Mahmud N, O'Brien L, Hall A, Sawyer E, Wilkinson R, Easton DF, Eeles RA. Hum Genet., 129:687-94.
• Hand pattern indicates prostate cancer risk. (2011) Rahman AA, Lophatananon A, Stewart-Brown S, Harriss D, Anderson J, Parker T, Easton D, Kote-Jarai Z, Pocock R, Dearnaley D, Guy M, O'Brien L, Wilkinson RA, Hall AL, Sawyer E, Page E, Liu JF; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology, Eeles RA, Muir K. British Journal of Cancer, 104:175-7.
• The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotient-Beta Expression in Tissue and Urine. (2010) Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, Evans DG, Blanco I, Mercer C, Rubinstein WS, Clowes V, Douglas F, Hodgson S,  Walker L,  Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J,  Kirk J, Lilja H, Easton DF, The IMPACT Study Steering Committee, The IMPACT Study Collaborators, UK GPCS Collaborators, Cooper C, Eeles RA, Neal DE PLoS ONE, Research Article, published 13 Oct 2010 10.1371/journal.pone.0013363.
• Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. (2010) Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology. British Journal of Cancer, 103:918-24.
• Mutation analysis of the MSMB gene in familial prostate cancer. (2010). Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, Field H, Guy M, Al Olama AA, Morrison J, O'Brien L, Wilkinson R, Hall A, Sawyer E, Muir K, Hamdy F, Donovan J, Neal D, Easton D, Eeles R. British Journal of Cancer, 102:414-8.
• Dietary Fat and early onset prostate cancer risk. (2010). Lophatananon A, Archer J, Easton D, Pocock R, Dearnaley D, Guy M, Kote-Jarai Z, O'Brien L, Wilkinson RA, Hall AL, Sawyer E, Page E, Liu JF, Barratt S, Rahman AA; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology, Eeles R, Muir K. Br J Nutr. 103:1375-80.
• Screening for prostate cancer: The way ahead. (2010). Kirby RS, Eeles RA, Kote-Jarai Z, Guy M, Easton D and Fitzpatrick JM BJU International, 105:295-297.
• Multiple loci on 8q24 associated with prostate cancer susceptibility. (2009) Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UKGPCS Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF. Nature Genetics, 41: 1058-60.
• Identification of seven novel prostate cancer susceptibility loci through a genome-wide association study. (2009) Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UKGPCS Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF. Nature Genetics, 41:1116-21.
• Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. (2009) Macinnis RJ, Antoniou AC, Eeles RA, Severi G, Guy M, McGuffog L, Hall AL, O’Brien LT, Wilkinson, RA, Dearnaley DP, Ardern-Jones AT, Horwich A, Khoo VS, Parker CC, Huddart RA, McCredie MR, Smith C, Southey MC, Staples MP, English DR, Hopper JL, Giles GG, Easton DF. Genetic Epidemiology. E-pub June 2009.
• Association of folate-pathway gene polymorphisms with the risk of prostate cancer: A population-based nested case-control study, systematic review and meta-analysis. (2009) Collin SM, Zuccolo L, Chen L, Lewis SJ, Metcalfe C, Cox A, Davis M, Lane JA, Donovan J,  Davey Smith G, Neal DE, Hamdy FC, Gudmundsson J, Sulem P, Rafnar T, Benediktsdottir KR, Eeles RA, Guy M, Kote-Jarai Z, Morrison J, Al Olama AA, UKGPCS Group, Stefansson K, Easton DF, Martin RM. Cancer Epidemiology Biomarkers & Prevention, 18:2528-39.
• Sexual activity and prostate cancer risk in men diagnosed at a younger age. (2009) Dimitropoulou P, Lophatananon A, Easton D, Pocock R, Dearnaley DP, Guy M, Edwards S, O’Brien L, Hall A, Wilkinson R, The UKGPCS Collaborators, BAUS Section of Oncology, Eeles R, Muir KR. British Journal of Urology International. 103:178-85.
• A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. (2009) Kote-Jarai Z, Jugurnauth S, Mulholland S, Leongamornlert DA, Guy M, Edwards S, Tymrakiewitcz M, O’Brien L, Hall A, Wilkinson R, Amin Al Olama A, Morrison J, The UKGPCS Collaborators, The British Association of Urological Surgeons’ Section of Oncology, Muir K, Neal D, Donovan J, Hamdy F, Easton D, Eeles R. British Journal of Cancer, 100:426-430.
• Review: Identification of new genetic risk factors for prostate cancer. (2009) Guy M, Kote-Jarai Z, Giles GG, Al Olama AA, Jugurnauth SK, Mulholland S, Leongamornlert D, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O’Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, The UKGPCS Collaborators, BAUS Section of Oncology, The UK ProtecT Study Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jameson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF, Eeles RA. Asian Journal of Andrology, 11:49-55.
• Reply to "Variation in KLK genes, prostate-specific antigen and risk of prostate cancer". (2008) Eeles R, Giles G, Neal D, Muir K, Easton DF; for the PRACTICAL Consortium. Nature Genetics, 40:1035-1036.
• Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Study. (2008) Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N,  Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schurmann SK, Schurmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O’Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA, PRACTICAL Consortium, Eeles RA. Cancer Epidemiology Biomarkers & Prevention, 17:2052-61
• Multiple Loci with Different Cancer Specificities Within the 8q24 Gene Desert. (2008) Ghoussaini M, Song H, Koessler  T, Amin Al Olama A, Kote-Jarai  Z, Driver K, Pooley  KA, Ramus SJ, Krüger Kjaer S, Hogdall E,  DiCioccio RA, Whittemore AS, Gayther SA, Giles GG, Guy M, Edwards SM, Morrison J, Donovan JL, Hamdy FC, Dearnaley DP, Ardern-Jones AT, Hall AL, O’Brien LT, Gehr-Swain BN, Wilkinson RA, Brown PM, The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology, The UK ProtecT Study Collaborators, Hopper JL, Neal DE, Pharoah PDP, Ponder BAJ, Eeles RA, Easton DF, Dunning AM. Journal of the National Cancer Institute, 100:962-6.
• Diagnostic radiation procedures and risk of prostate cancer. (2008) Myles P, Evans S, Lophatananon A, Dimitropoulou P, Easton D, Key T, Pocock R, Dearnaley D, Guy M, Edwards S, O’Brien L, Gehr-Swain B, Hall A, Wilkinson R, Eeles R, Muir K. British Journal of  Cancer, 98:1852-6.
• Multiple newly identified loci associated with prostate cancer susceptibility (2008) Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G , Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, The UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, The UK ProtecT Study Collaborators, Horwich A, Huddart RA , Khoo VS , Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Nature Genetics, 40:316-321.
• Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. (2006) Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh CL, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TL, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA. Human Genetics, 120:471-85.
• Description of the International Consortium for Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13. (2005) Schaid DJ, Chang BL and The International Consortium for Prostate Cancer Genetics (ICPCG) and ACTANE consortium: Eeles R, Edwards S, Hope Q, Bullock S et al. The Prostate, 63:276-290.
• Association between hormonal genetic polymorphisms and early-onset prostate cancer. (2005) Forrest MS, Edwards SM, Houlston  R, Kote-Jarai Z, KeyT, Allen N, Knowles MA, Turner F, Ardern-Jones A, Murkin A, Williams S, Oram R, CR-UK/BPG UK prostate cancer study collaborators,  Bishop DT and Eeles RA. Prostate Cancer Prostatic Diseases, 8:95-102.
• A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. (2005) Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D, ACTANE Consortium. American Journal of Human Genetics,77:219-29.
• Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer.(2005) Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnaley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Moller P, Maehle L, Badzioch M, Eeles RA, Easton DF, English DR, Southey MC, Hopper JL, Foulkes WD, Giles GG; The Cancer Research UK/British Association of Urological Surgeons’ Section of Oncology Collaborators. Cancer Epidemiology Biomarkers & Prevention. 14:397-402.
• ATM polymorphisms as risk factors for prostate cancer development. (2004) Angèle S, Falconer A, Edwards SM, Dörk T, Bremer M, Moullan N, Chapot B, Muir K, Houlston R, Norman AR, Bullock S, Hope Q, Meitz J, Dearnaley D, Dowe A, Southgate C, Ardern-Jones A, Easton DF, Eeles RA, Hall J. British  Journal of Cancer, 91: 783-87.
• ATM over-expression in prostate tumours: possible role in telomere maintenance. (2004) Angèle S, Falconer A, Foster CS, Taniere P, Eeles RA  & Hall J. American Journal of Clinical Pathology. 121: 231-6.
• Results of a Genome-Wide Linkage Analysis in Prostate Cancer Families Ascertained Through the ACTANE Consortium.(2003) Edwards S, Meitz J, Eeles R, Evans C, Easton D, Hopper J, Giles G, Foulkes WD, Narod S, Simard J, Badzioch M, Mahle L, The International ACTANE Consortium. The Prostate, 57: 270-79.
• Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. (2003) Bevan S, Edwards SM, Ardern-Jones A, Dowe A, Southgate C, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Dearnaley D, Easton DF, Eeles RA, Houlston RS. Prostate Cancer Prostatic Diseases 6: 12-4.
• Association between Leptin Receptor Gene Polymorphisms and Early Onset Prostate Cancer. Kote-Jarai Z, Singh R, Durocher F, Easton D, Edward SM, Ardern-Jones A, Dearnaley DP, Houlston R, Kirby R, Eeles R (2003) British Journal of  Urology International, 92:109-12. 
• Two percent of men with early onset prostate cancer harbour germline mutations in the BRCA2 gene. (2003) Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley D, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare D, Ponder B, Gayther  S, The CRC/BPG UK Familial Prostate Cancer Study Collaborators/BAUS Section of Oncology, Easton DF & Eeles RA. American Journal of Human Genetics, 72:1-12.
• Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer. Kote-Jarai Z, Durocher F, Edwards SM, Hamoudi R, Jackson RA, Ardern-Jones A, Murkin A, Dearnaley DP, Houlston R, The CRC/BPG UK Familial Prostate Cancer Collaborators, Easton DF, & Eeles RA. Prostate Cancer and Prostatic Diseases, 5:189-92.
• Influence of cytokine polymorphisms on the development of prostate cancer. (2002) McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley D, Dowe A, Southgate C, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Easton DF, Eeles RA  & Howell WM. Cancer Research, 62:3369-72.
• HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. (2002) Meitz J, Edwards S, Easton D, Murkin A, Ardern-Jones A, Jackson R, Williams S, Dearnaley D, Stratton M, Houlston R, The CRC/BPG UK Familial Prostate Cancer Study Collaborators & Eeles RA.  British Journal of Cancer, 87:905-8.
• Relationship between Glutathione S-Transferase M1, P1, and T1 polymorphisms and early onset prostate cancer. (2001) Kote-Jarai Z, Easton D, Edwards SM, Jefferies S, Jackson RA, Ardern-Jones A, Murkin A, Durocher F, Dearnaley DP, Singh R, Shearer R, Kirby R, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Houlston R, Eeles RA. Pharmacogenetics, 11:325-30.
• No evidence of germline PTEN mutations in familial prostate cancer. (2000) Forrest MS, Edwards SM, Hamoudi RA, Dearnaley DP, Ardern-Jones A, Dowe A, Murkin A, Kelly J, Teare MD, Easton DF, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, The EC BIOMED Familial Prostate Cancer Study Collaborators, Knowles MA, Bishop DT & Eeles RA. Journal of Medical Genetics, 37:210-12.
• Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. (2000) Jianfeng Xu & International Consortium for Prostate Cancer Genetics (ICPCG) incl Eeles RA. American Journal of Human Genetics, 66:945-57.
• No evidence of linkage to chromosome 1q42.2-43 in 131 prostate cancer families from the ACTANE consortium. (2000) Singh R and The ACTANE Consortium & Eeles RA. British Journal of Cancer, 83:1654-8.
• Suggestive evidence for a site specific prostate cancer gene on 1p36. (2000) Badzioch M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar D, Hopper JL, Bishop DT, Moller P, Heimdahl K, Easton D, The CRC/BPG Familial Prostate Cancer Study Coordinators and Collaborators, The EU Biomed Collaborators, Simard J. Journal of  Medical Genetics 37:947-8.
• The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. (2000) Gayther SA, de Foy KAF, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, The CRC/BPG United Kingdom Familial Prostate Cancer Study Collaborators, Ponder BAJ, Barnes D and Eeles RA. Cancer Research, 60: 4513-18.
• High Risk Genes Predisposing to Prostate Cancer Development – Do they Exist? (2000) Singh R, Eeles RA, Durocher F, Simard J, Edwards SM, Badzioch M, Kote-Jarai Z, Teare D, Ford D, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, Labrie F, The CRC/BPG UK Familial Prostate Cancer Collaborators, Easton D, Narod A, Tonin PN, Foulkes W. Prostate Cancer & Prostatic Diseases, 3:241-7.
• Genetic predisposition to prostate cancer.  (1999) Eeles RA, the UK Familial Prostate Study Co-ordinating Group & the CRC/BPG UK Familial Prostate Cancer Study Collaborators Prostate Cancer & Prostatic Diseases 2: 9-15.
• Linkage analysis of chromosome 1q markers in 136 prostate cancer families. (1998) Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, Gill S, Biggs P, Dearnaley D, Ardern-Jones A, Dowe A, Shearer R, McLennan DL, Norman RW, Ghadirian P, Aprikian A, Ford D, Amos C, King TM, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Simard J, Narod S, Easton D & Foulkes W. American Journal of Human Genetics, 62: 653-8.
• Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. (1998) Edwards SM, Dunsmuir WD, Gillett C, Lakhani SR, Corbishley C, Young M, Kirby RS, Dearnaley DP, Dowe A, Ardern-Jones A, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Barnes D & Eeles RA. International Journal of Cancer 78:1-7.
• Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. (1998) Dunsmuir WD, Edwards SM, Lakhani SR, Young M, Corbishley C, Kirby RS, Dearnaley DP, Dowe A, Ardern-Jones A, Kelly J, The CRC/BPG UK Familial Prostate Cancer Study Collaborators & Eeles RA. British Journal of Cancer 78:1430-3.
• No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. (1997) Edwards S, Dearnaley DP, Ardern-Jones A, Hamoudi R, Easton DF, Ford D, Shearer R, Dowe A, CRC/BPG UK Familial Prostate Cancer Study & Eeles RA. British Journal of Cancer, 76: 992-1000.
• Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. (1997) Eeles RA, Dearnaley DP, Ardern-Jones A, Shearer RJ, Easton DF, Ford D, Edwards S & Dowe A. British Journal of Urology, 79: 8-14.